Mycobacteria embrace a broad pool of microorganisms causing infections with renowned impact in human health causing altogether millions of deaths every year. From tuberculosis and lepra, caused by Mycobacterium tuberculosis and Mycobacterium leprae respectively, to infections caused by emergent/opportunistic pathogens such as Mycobacterium abscessus. The battle to confront this health burden is further challenged by limitations in the treatments currently available and the emergence of antimicrobial resistance, thus making necessary the search for new therapeutic strategies to fight these infections. Mycobacteriophage LysA endolysins are complex multi-domain peptidoglycan hydrolyses with reported antimicrobial relevance and potential to treat mycobacterial infections. However, and despite the therapeutic prospective of LysAs, a profound understanding of their mechanism of action still remains limited. The present work provides a thorough structural-functional study of the catalytic domains of two LysA endolysins encoded by the bacteriophages D29 and DS6A, known to infect pathogenic mycobacteria including M. tuberculosis. As part of this study, we have characterised the four catalytic domains bared by both endolysins (D29N4/D29GH19 and DS6AGH19/DS6AAmi2B) alone and in complex with PG analogues. To do so, our approach was to combine protein engineering, X-ray crystallography, small-angle X-ray scattering and in silico tools that, to our knowledge, it has yielded the first experimental structures reported for mycobacteriophage endolysins. Our study unravels major aspects of peptidoglycan-binding and hydrolysis by D29LysA and DS6ALysA lysins and other homologue LysAs, including the hydrolase domains alike to the ones here examined. Altogether, this constitutes an important step forward for understanding how the mycobacterial cell-wall hydrolysis is done by this relevant class of endolysins and, opening the path for their future use in their therapeutic exploration as enzybiotics, allowing the rational design of a la carte enzymes with optimised lytic properties against mycobacterial pathogens.